Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
| Stock | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| MPLTMapLight Therapeutics, Inc. | Catalyst4, Inc.10% Owner | $15.3M | Added | |||
| Bought 1,209,225 shares across 4 transactions Jul 28–30 at prices ranging $10.74–$13.00 (avg ~$12.66); stock now $14.03 (+10.8%). Stock hit all-time low $9.10 on Jul 28. Positive Phase 2 ZEPHYR results Jul 27. Director Troy Cox also bought $149K on Jul 28 (below threshold). Catalyst4 held ~19.7M shares pre-purchase; post-purchase 20.9M shares. | ||||||
| ACIAlbertsons Companies, Inc. | Susan MorrisCEO | $450K | Added | |||
| Bought 39,409 shares at prices ranging $11.377–$11.455 (avg $11.42) on Jul 28; stock now $11.60 (+1.6%). Cluster: EVP Thomas Moriarty bought $1.96M at $11.51 on Jul 27 (filed Jul 28). Combined two-day cluster buy ~$2.4M near multi-year lows. | ||||||
| NMMNavios Maritime Partners L.P. | Angeliki FrangouCEO & Chairwoman | $251K | Added | |||
| 3 tranches: Jul 28 (1,072 @ $78.59), Jul 29 (1,051 @ $78.55), Jul 30 (1,068 @ $78.37); stock now $79.27 (+0.9%). Executed via Rule 10b5-1 plan adopted Dec 9, 2025 through affiliated entity Raymar Investments S.A. Systematic accumulation — reduced signal value vs. discretionary buy. | ||||||
Scanned the last 24 hours of EDGAR Form 4 filings (filed July 30–31, 2026). 3 qualifying buys (≥ $250K, transaction type P) totalling $16.0M.
Thin buying day overall — scanning 1,600+ Form 4 filings yielded only 3 open-market purchases above $250K. The vast majority were routine RSU grants (code A), option exercises (code M), insider sales (code S), and pre-arranged 10b5-1 disposals.
MPLT dominates at $15.3M: MapLight Therapeutics (CNS biotech, NASDAQ) saw 10% owner Catalyst4 aggressively accumulate near all-time lows ($9.10 on Jul 28). Stock has already recovered to $14.03 as of Jul 31, putting Catalyst4 up +10.8% on the position. Positive Phase 2 ZEPHYR trial results were reported Jul 27. Director Troy Cox also made an open-market buy of $149K on Jul 28 (below $250K threshold — noted for cluster context). Heavy buying signal at the lows.
ACI cluster forming: Albertsons CEO Susan Morris's $450K buy on Jul 28 follows EVP of M&A Thomas Moriarty's $1.96M buy on Jul 27 (filed Jul 28 — just outside our 24-hour window). Two Albertsons insiders bought a combined ~$2.4M in two consecutive days near $11.40–$11.51 — the stock has been under sustained pressure following the collapse of the Kroger merger. Stock now at $11.60, barely above the buy zone.
NMM/Frangou is systematic: Purchased through a Rule 10b5-1 trading plan adopted December 9, 2025, via affiliate Raymar Investments S.A. Routine accumulation — lower signal value than a discretionary buy, but Frangou has a long history of conviction buying in Navios entities.
Close misses: LBRT Director Arjun N. Murti bought 14,053 shares at $17.79 avg on Jul 28 (total: $249,909 — just $91 below the $250K threshold). SCTX (Scribe Therapeutics) saw massive IPO-related buys by OrbiMed ($15M) and Carl Gordon ($15M) on Jul 27 filed Jul 29 — outside our 24-hour window but notable for the sector.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.